Year: 2026

New Lawson Analog Target Identified Near Original Discovery on Genesis TrendBracken Well at Grasslands Project, 325 km southwest of Lawson Discovery, is successfully cased after being drilled to a total depth of 2,600 meters  Mixed gas interval with Helium and Natural Hydrogen encountered in Upper Devonian at Bracken, followed by two Natural Hydrogen-dominant zones in basal Deadwood and Basement Complex; service rig operations for well completion and testing phase to begin after spring breakup Lawson “look-a-like” target identified just 12 km southwest of original Lawson Discovery, based on further review of legacy 2D seismic data High quality data set delivered from a 3D Seismic Survey completed on Genesis Trend covering 47 sq. km at the Lawson Natural Hydrogen Discovery and a broad area surrounding the Lawson Well – initial interpretations...

NEW YORK, April 2, 2026—Wix.com Ltd. (Nasdaq: WIX) (“Wix” or the “Company”) today announced the preliminary results of its “modified Dutch Auction” tender offer, which expired at one (1) minute after 11:59 P.M., New York City time, on April 1, 2026.  Based on the preliminary count by Equiniti Trust Company, LLC, the depositary for the tender offer (the “Depositary”), a total of 18,718,009 of Wix’s ordinary shares, par value NIS 0.01 per share (each, a “Share,” and collectively, the “Shares”), were properly tendered and not properly withdrawn at or below the purchase price of $92.00 per share. In accordance with the terms and conditions of the tender offer, and based on the preliminary count by the Depositary, Wix expects to accept for payment a total of 18,718,009 Shares, representing all Shares that were properly tendered and not properly...

All amounts are in United States dollars, unless otherwise stated. TORONTO, April 02, 2026 (GLOBE NEWSWIRE) —  Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) plans to release its first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Senior management will host a conference call on Thursday, April 30, 2026 at 11:00 am ET to discuss the results. The Company will hold its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) on Thursday, May 28, 2026. Notice of First Quarter 2026 Results and Conference Call Participants may join the conference call via webcast or through the following dial-in numbers: Via Webcast: To view the live webcast, please register at www.alamosgold.com, or through the following link view webcast. Via Phone:         Toronto and International: (647)...

Seattle, WA, April 02, 2026 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), and RTB Digital Inc.’s (Roundtable) CEO, James Heckman, announced today that the merger was approved at the Company’s Special Meeting of Shareholders held on April 1, 2026. The approval removes the final corporate hurdle to complete the merger, and, subject to Nasdaq approval of Roundtable’s initial listing application, which has been filed, establishes the foundation to list the combined company on Nasdaq as RTB Digital Inc., expected to be listed under the ticker symbol RTB. The transaction is anticipated to consummate imminently. “We are grateful for the outcome of today’s Special Meeting and appreciate RYVYL stockholders’ support for the merger,” said Heckman, founder and CEO of Roundtable. “In anticipation of bringing...

Paris, April 02, 2026 ANNUAL FINANCIAL REPORT 2025 In accordance with the regulatory requirements in force, Sfil announces that the French version of its Annual Financial Report 2025 was filed with the Autorité des Marchés Financiers (AMF) on April 02, 2026, and that it can be obtained from its website: https://sfil.fr/resultats-et-publications/ The English version of the Annual Financial Report 2025 will be available around mid-April 2026 on the website: https://sfil.fr/en/results-and-publications/AttachmentRFA Sfil 2025 Communiqué mise à dispo EN

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib’s expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026 Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint;...